BioSpace News Archive

Angle PLC Announces Predicting Immunotherapy Response in SCLC

ANGLE plc, a world-leading liquid biopsy company, is pleased to announce that the Edith Cowan University, Perth, Australia, has published results from a study in small cell lung cancer patients using the Parsortix® system.

June 16, 2022
·
9 min read
Natalie Berner of Redmile and Nanna Lüneborg of Forbion proposed as New Board Members of BioInvent

BioInvent International AB announces on behalf of the nomination committee, the proposal to elect Natalie Berner and Nanna Lüneborg as new Board members, at the Extraordinary General Meeting on July 12, 2022.

June 16, 2022
·
4 min read
Vicore announces first human dosed with novel ATRAG, C106

Vicore Pharma Holding AB announces initiation of a first-in-human trial with the novel ATRAG C106.

June 16, 2022
·
2 min read
Business

Year-end Report 2021/2022 - Preparations for the Upcoming US Launch

The high point of the quarter was when we submitted our 510(k) application to the US Food and Drug Administration (FDS) for market approval of DiviTum®TKa.

June 16, 2022
·
5 min read
Drug Development

Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a Rare Neuromuscular Disease

Biophytis SA announced that it is presenting new preclinical efficacy data for its product Sarconeos in SMA at the SMA Cure 2022 conference in Anaheim, California, USA on June 16-19, 2022.

June 16, 2022
·
4 min read
Nykode Therapeutics uplisted to the main list of the Oslo Stock Exchange

Nykode Therapeutics ASA announced that it has been uplisted to the main list of the Oslo Stock Exchange with first day of trading today, June 16, 2022.

June 16, 2022
·
2 min read
Business

111, Inc. Announces First Quarter 2022 Unaudited Financial Results

111, Inc. today announced its unaudited financial results for the first quarter ended March 31, 2022 .

June 16, 2022
·
19 min read
Business

Encision Reports Fourth Quarter Fiscal Year 2022 Results

Encision Inc. announced financial results for its fiscal 2022 fourth quarter that ended March 31, 2022.

June 16, 2022
·
7 min read
Pharm Country

atai Life Sciences to Participate in Upcoming June Healthcare Conferences

atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming healthcare conferences.

June 16, 2022
·
2 min read
Policy

Nammi Therapeutics Granted FDA Orphan Drug Designation For QXL138AM for the Treatment of Pancreatic Cancer

Nammi Therapeutics, Inc., a Los Angeles based immunotherapy company, announced that the US Food and Drug Administration has granted orphan drug designation to its lead program, QXL138AM, for the treatment of Pancreatic Cancer.

June 16, 2022
·
2 min read